@article{fb353a071b554f699426ac510c6c67b2,
title = "Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer",
abstract = "Patients with cancer are more likely to have impaired immune responses to SARS-CoV-2 vaccines. We study the breadth of responses against SARS-CoV-2 variants after primary vaccination in 178 patients with a variety of tumor types and after booster doses in a subset. Neutralization of alpha, beta, gamma, and delta SARS-CoV-2 variants is impaired relative to wildtype, regardless of vaccine type. Regardless of viral variant, mRNA1273 is the most immunogenic, followed by BNT162b2, and then Ad26.COV2.S. Neutralization of more variants (breadth) is associated with a greater magnitude of wildtype neutralization, and increases with time since vaccination; advancing age associates with a lower breadth. The concentrations of anti-spike protein antibody are a good surrogate for breadth (positive predictive value of =90\% at >1,000 U/mL). Booster SARS-CoV-2 vaccines confer enhanced breadth. These data suggest that achieving a high antibody titer is desirable to achieve broad neutralization; a single booster dose with the current vaccines increases the breadth of responses against variants.",
keywords = "Ad26.COV2.S, BNT162b2, booster dose, breadth, cancer, mRNA1273, neutralization, SARS-CoV-2, variants",
author = "Vivek Naranbhai and \{St. Denis\}, \{Kerri J.\} and Lam, \{Evan C.\} and Onosereme Ofoman and Garcia-Beltran, \{Wilfredo F.\} and Mairena, \{Cristhian B.\} and Bhan, \{Atul K.\} and Gainor, \{Justin F.\} and Balazs, \{Alejandro B.\} and Iafrate, \{A. John\} and \{on behalf of the CANVAX team\}",
note = "Funding Information: We thank the Peter and Ann Lambertus Family Foundation and Donald Glazer for support of the CANVAX study. We thank Andrea Nixon and the MGH Core laboratory for assistance in performing assays. We thank Michael Farzan, PhD, for providing ACE2-expressing 293T cells. A.J.I. and this study were supported by the Peter and Ann Lambertus Family Foundation. A.B.B. was supported by the National Institutes for Drug Abuse (NIDA) Avenir New Innovator Award DP2DA040254, the MGH Transformative Scholars Program as well as funding from the Charles H. Hood Foundation. Research support: Peter and Ann Lambertus Family Foundation; Donald Glazer Fund, Conceptualization, V.N. A.J.I. Methodology, V.N. J.F.G. A.B.B, A.J.I. W.F.G.B., Formal Analysis, V.N. K.J.S.D, E.C.L. Investigation, V.N. K.J.S.D, E.C.L, O.O. W.F.G.B. C.B. A.B.B. Data Curation, V.N. Writing—Original Draft, V.N. Writing—Review and Editing, V.N. K.J.S.D, E.C.L, O.O. W.F.G.B. C.B. A.B. J.F.G. A.B.I. A.J.I. Visualization, V.N. Supervision, J.F.G. A.B.B, A.J.I. Funding Acquisition, J.F.G. A.B.B, A.J.I. J.F.G. has served as a compensated consultant or received honoraria from Bristol-Myers Squibb, Genentech, Ariad/Takeda, Loxo/Lilly, Blueprint, Oncorus, Regeneron, Gilead, Moderna, AstraZeneca, Pfizer, Novartis, Merck, and GlydeBio; research support from Novartis, Genentech/Roche, and Ariad/Takeda; institutional research support from Bristol-Myers Squibb, Tesaro, Moderna, Blueprint, Jounce, Array Biopharma, Merck, Adaptimmune, Novartis, and Alexo; and has an immediate family member who is an employee with equity at Ironwood Pharmaceuticals. A.J.I. has served as a compensated consultant for Oncoclinicas Brasil, Kinnate, Repare, and Paige.ai. We worked to ensure gender balance in the recruitment of human subjects. We worked to ensure ethnic or other types of diversity in the recruitment of human subjects. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in science. One or more of the authors of this paper self-identifies as a member of the LGBTQ+ community. While citing references scientifically relevant for this work, we also actively worked to promote gender balance in our reference list. Funding Information: We thank the Peter and Ann Lambertus Family Foundation and Donald Glazer for support of the CANVAX study. We thank Andrea Nixon and the MGH Core laboratory for assistance in performing assays. We thank Michael Farzan, PhD, for providing ACE2-expressing 293T cells. A.J.I. and this study were supported by the Peter and Ann Lambertus Family Foundation . A.B.B. was supported by the National Institutes for Drug Abuse (NIDA) Avenir New Innovator Award DP2DA040254, the MGH Transformative Scholars Program as well as funding from the Charles H. Hood Foundation . Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",
year = "2022",
month = jan,
day = "10",
doi = "10.1016/j.ccell.2021.12.002",
language = "English",
volume = "40",
pages = "103--108.e2",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "1",
}
